top of page
Executive Spotlights

Origami Surgical Inc. announces FDA clearance for a label expansion

Madison, NJ, February 21, 2023 (Origami Surgical) -- Origami Surgical has received a new FDA clearance for the insertion and removal of our StitchKit® device. This new FDA indication allows for insertion or removal through any existing 8 mm trocar incision while the surgeon is watching the action via the laparoscope – allowing StitchKit® use even when no 12 mm trocars are in use. The simple technique involves removal of one 8mm trocar followed by direct placement (by the surgeon) of StitchKit® into the surgical field through the trocar incision. At the end of the case, the surgeon then removes StitchKit® via the retrieval string – pulling it flush to robotic trocar and removing the trocar and StitchKit® as a unit.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page